Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Amitabha Bhaumik"'
Autor:
Byung Ha Chung, Jian Huang, Hiroji Uemura, Young Deuk Choi, Zhang-Qun Ye, Hiroyoshi Suzuki, Taek Won Kang, Da-Lin He, Jae Young Joung, Sabine D Brookman-May, Sharon McCarthy, Amitabha Bhaumik, Anildeep Singh, Suneel Mundle, Simon Chowdhury, Neeraj Agarwal, Ding-Wei Ye, Kim N Chi, Hirotsugu Uemura
Publikováno v:
Asian Journal of Andrology, Vol 25, Iss 6, Pp 653-661 (2023)
The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial showed improvement in overall survival (OS) and other efficacy endpoints with apalutamide plus androgen deprivation therapy (ADT) versu
Externí odkaz:
https://doaj.org/article/c78d4747b1574342b443336c6734afee
Autor:
Gordon Brown, Laurence Belkoff, Jason M. Hafron, Daniel R. Saltzstein, Rushikesh Potdar, Amitabha Bhaumik, Jennifer Phillips, Tracy McGowan, Neal D. Shore
Publikováno v:
Targeted Oncology. 18:95-103
The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2aa8415cb162a6313dc0696bc30198
https://doi.org/10.1007/s11523-022-00932-8
https://doi.org/10.1007/s11523-022-00932-8
Autor:
Fred Saad, Eric J. Small, Felix Y. Feng, Julie N. Graff, David Olmos, Boris A. Hadaschik, Stéphane Oudard, Anil Londhe, Amitabha Bhaumik, Angela Lopez-Gitlitz, Shibu Thomas, Suneel D. Mundle, Simon Chowdhury, Matthew R. Smith
Background: Apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS), overall survival (OS), and time to prostate-specific antigen (PSA) progression in the placebo-controlled SPARTAN study of high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457638f43d48029d906eef11930a89db
https://www.ncbi.nlm.nih.gov/pubmed/34916086
https://www.ncbi.nlm.nih.gov/pubmed/34916086
Autor:
YaoYao Pollock, Matthew R. Smith, Fred Saad, Simon Chowdhury, Stéphane Oudard, Boris Hadaschik, David Olmos, Ji Youl Lee, Hiroji Uemura, Amitabha Bhaumik, Anil Londhe, Brendan Rooney, Sabine D. Brookman-May, Peter De Porre, Suneel D. Mundle, Eric J. Small
Publikováno v:
Prostate cancer and prostatic diseases.
Background: The phase III SPARTAN study demonstrated that apalutamide significantly improves metastasis-free survival and overall survival vs. placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). However, patients re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54149789655884f2f8d8b035d4b1aa59
https://pubmed.ncbi.nlm.nih.gov/36209239
https://pubmed.ncbi.nlm.nih.gov/36209239
Autor:
Anders Bjartell, Kim N. Chi, Lawrence Karsh, Sabine Brookman-May, Clemente Aguilar-Bonavides, Álvaro Juárez Soto, Shibu Thomas, Simon Chowdhury, Robert Given, Andrea J. Pereira de Santana Gomes, Florence Lefresne, Sharon Anne McCarthy, Suneel Mundle, Neeraj Agarwal, Axel S. Merseburger, Hirotsugu Uemura, Amitabha Bhaumik, Justin Lucas
Publikováno v:
Journal of Urology. 206
INTRODUCTION AND OBJECTIVE:The final analysis of TITAN confirmed improvement in long-term outcomes in metastatic castration-sensitive prostate cancer (mCSPC) with apalutamide (APA) + androgen depri...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1ed636f2f3f0dff9e643405321147cc
https://doi.org/10.1097/ju.0000000000002015.08
https://doi.org/10.1097/ju.0000000000002015.08
Autor:
Susan Feyerabend, J. Shen, Neeraj Agarwal, Lawrence Karsh, Katherine B. Bevans, Sharon Anne McCarthy, Simon Chowdhury, J.N. Graff, Suneel Mundle, Brendan Rooney, Christopher Michael Pieczonka, Kim N. Chi, Matthew R. Smith, Stéphane Oudard, Benjamin A. Gartrell, Eric J. Small, Anil Londhe, Fred Saad, Sabine Brookman-May, Amitabha Bhaumik
Publikováno v:
Annals of Oncology. 32:S656-S657
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad73bf5d2f017fbd20a74fac5658a7da
https://doi.org/10.1016/j.annonc.2021.08.1131
https://doi.org/10.1016/j.annonc.2021.08.1131
Autor:
Kim N. Chi, Axel S. Merseburger, Mustafa Ozguroglu, Simon Chowdhury, Anders Bjartell, Byung Chung, Andrea Juliana Pereira de Santana Gomes, Robert Given, Álvaro Juárez, Hirotsugu Uemura, Dingwei Ye, Lawrence Ivan Karsh, Benjamin Adam Gartrell, Sabine D. Brookman-May, Suneel Mundle, Sharon Anne McCarthy, Florence Lefresne, Oliver Brendan Rooney, Amitabha Bhaumik, Neeraj Agarwal
Publikováno v:
Journal of Clinical Oncology. 40:89-89
89 Background: Addition of androgen receptor signaling inhibitors to ADT + DOC has been shown to improve clinical outcomes in pts with mCSPC. TITAN, a placebo-controlled phase 3 study, showed that APA + ADT improved overall survival (OS) and other cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52e744de24726b1d85027d4212431011
https://doi.org/10.1200/jco.2022.40.6_suppl.089
https://doi.org/10.1200/jco.2022.40.6_suppl.089
Autor:
Paul Mitchell, Amitabha Bhaumik, Philip G Hykin, Sebastian Wolf, Jun Li, Timothy Y Y Lai, Andreas Wenzel, Giovanni Staurenghi
Publikováno v:
Ophthalmology. 125:850-862
Purpose To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular edema (ME) resulting from any cause other than diabetes, retinal vein occlusion, or neovascular age-related macular degeneration. Design A phase 3, 12-mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f7bd034bab35f41b6f61fc8d4ac435c
https://doi.org/10.1016/j.ophtha.2017.12.002
https://doi.org/10.1016/j.ophtha.2017.12.002
Autor:
M.A.J. Rios, J.A. Rinck, Amitabha Bhaumik, M. Grings, A. Mota, S. Campos-Gomez, A. Acerbi, Felipe Melo Cruz, K. Salomão, J.C. Ochoa, R. Gidekel, V. Fabricio
Publikováno v:
Annals of Oncology. 32:S1370
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0df3697a3c13456825e18b1827450c0
https://doi.org/10.1016/j.annonc.2021.08.2077
https://doi.org/10.1016/j.annonc.2021.08.2077
Autor:
Suneel Mundle, Andrea J. Pereira, Vanessa Fabricio, Sharon Anne McCarthy, Sara Rosas, Álvaro Juárez, Neeraj Agarwal, Esteban Velasquez, Amitabha Bhaumik, Simon Chowdhury, Spyros Triantos, Kim N. Chi
Publikováno v:
Cancer Research. 81:CT190-CT190
Background: Apalutamide (APA) is an approved treatment in various countries of Latin America to treat patients with metastatic hormone-sensitive prostate cancer (mCSPC) patients based on the TITAN study interim analysis, which demonstrated an improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d95adc2a6310b7bb6fce533550f27d75
https://doi.org/10.1158/1538-7445.am2021-ct190
https://doi.org/10.1158/1538-7445.am2021-ct190